[Acute promyelocytic leukemia associated with hemophagocytic syndrome]. 2007

Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
Department of Hematology, Tokyo Medical and Dental University.

A 19-year-old man was referred to our hospital with pancytopenia and disseminated intravascular coagulation (DIC). Bone marrow aspiration revealed 93.6% of atypical promyelocytes and marked hemophagocytosis by macrophages. The diagnosis of acute promyelocytic leukemia (APL) associated with hemophagocytic syndrome (HPS) was made. As there was no evidence of infection, collagen diseases, or abuse of medicine, his HPS was classified as malignancy-associated HPS (MAHS). The DIC improved after administration of idarubicin and all-trans-retinoic acid (ATRA). On the 11th day, however, DIC and elevation of serum LDH recurred with the appearance of hepatosplenomegaly. Although APL cells had decreased in the bone marrow, hemophagocytes persisted. After administration of dexamethasone and etoposide, DIC and HPS improved, and complete remission of APL was obtained. ATRA was implicated in the aggravation of APL-induced MAHS in the present case.

UI MeSH Term Description Entries
D008297 Male Males
D010198 Pancytopenia Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets. Pancytopenias
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D004211 Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS. Consumption Coagulopathy,Coagulation, Disseminated Intravascular,Disseminated Coagulation, Intravascular,Intravascular Coagulation, Disseminated,Intravascular Disseminated Coagulation,Coagulation, Intravascular Disseminated,Coagulations, Disseminated Intravascular,Coagulations, Intravascular Disseminated,Coagulopathies, Consumption,Coagulopathy, Consumption,Consumption Coagulopathies,Disseminated Coagulations, Intravascular,Disseminated Intravascular Coagulations,Intravascular Coagulations, Disseminated,Intravascular Disseminated Coagulations
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014212 Tretinoin An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). Retinoic Acid,Vitamin A Acid,Retin-A,Tretinoin Potassium Salt,Tretinoin Sodium Salt,Tretinoin Zinc Salt,Vesanoid,all-trans-Retinoic Acid,beta-all-trans-Retinoic Acid,trans-Retinoic Acid,Acid, Retinoic,Acid, Vitamin A,Acid, all-trans-Retinoic,Acid, beta-all-trans-Retinoic,Acid, trans-Retinoic,Potassium Salt, Tretinoin,Retin A,Salt, Tretinoin Potassium,Salt, Tretinoin Sodium,Salt, Tretinoin Zinc,Sodium Salt, Tretinoin,Zinc Salt, Tretinoin,all trans Retinoic Acid,beta all trans Retinoic Acid,trans Retinoic Acid
D015255 Idarubicin An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA. 4-Demethoxydaunorubicin,4-Desmethoxydaunorubicin,IMI-30,Idarubicin Hydrochloride,NSC-256439,4 Demethoxydaunorubicin,4 Desmethoxydaunorubicin,Hydrochloride, Idarubicin,IMI 30,IMI30,NSC 256439,NSC256439

Related Publications

Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
June 2004, American journal of hematology,
Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
August 2011, Leukemia & lymphoma,
Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
May 2011, Pediatric blood & cancer,
Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
April 1963, Blood,
Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
July 1992, American journal of hematology,
Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
June 2021, American journal of ophthalmology case reports,
Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
January 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
January 2013, Acta haematologica,
Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
October 2000, Cancer genetics and cytogenetics,
Minako Jinta, and Ayako Arai, and Koh Yamamoto, and Chizuko Sakashita, and Tetsuya Fukuda, and Tohru Miu, and Takatoshi Koyama, and Naomi Murakami, and Osamu Miura
January 2011, Acta haematologica,
Copied contents to your clipboard!